Navigation Links
Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Date:7/18/2012

197944 have also been completed, which suggest an excellent margin of safety and tolerability.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, added: "We are delighted to announce the successful completion of Phase I clinical studies with CNV2197944.  We now plan to shortly initiate Phase II clinical trials with CNV2197944.  This will be the second compound originating from the spin-out from GSK in October 2010 that has successfully progressed to proof of concept in the chronic pain area, which is in real need for efficacious and safe pain treatments."  

The need for new drug treatments for chronic pain

The Pain therapeutic area encompasses any disease where pain is a major symptom. The unmet medical need for patients in pain is enormous, with the greatest need being for a more effective therapy that is well tolerated and safe over a long period of time. Within the pain marketplace, current pain treatments are unsatisfactory; overall efficacy is poor (typically 1-2 point reductions on a 10 point scale) and satisfactory to less than 50% of patients. Whilst treatments, such as opioids and non-steroidal anti-inflammatory drugs, are available on the market, many patients obtain little or no relief from these existing analgesics and often such drugs are associated with adverse events, side effects and addiction concerns. This highlights the importance of Convergence Pharmaceuticals' goals to be a world leader in the development of novel, efficacious analgesics with improved pharmacology and safety profiles.

About chronic pain

Currently, more than 1.5 billion people worldwide suffer from chronic pain of varying degrees. Among all types of chronic pain, neuropathic pain stands out with approximately 3-4.5% of the global population affected, with incidence rate increasing in line with increased age of the population. With the unmet clinical need so high, the demand for better pain management therapies, add
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Convergence of Art, Science and Beer
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
6. Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City
7. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
8. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
9. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
10. Questcor Pharmaceuticals Expands Repurchase Program
11. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... July 30, 2015 HIGHLIGHTS:Q2 2015 ... 2014) , Reported sales were $697 million compared ... Sales grew organically by 8%, and changes in foreign ... increased sales by 1%. , By business unit, ... Applied and 11% in SAFC Commercial. , Reported ...
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as a ... technical service business units, Whitehouse Laboratories is pleased to announce that it has begun ... Container Center of Excellence and will be strictly dedicated to basic USP 51, USP 61, ...
(Date:7/29/2015)... , July 30, 2015 ... reports results for the second quarter of 2015. ... group,s results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics ... Q2 results - Performance drivers ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... RALEIGH, N.C., April 3, 2008 Campbell Alliance, ... and,biotech industries, today announced that its Managed Markets ... Bio/Pharmaceutical Forum on Effective,Product Pricing and Modeling Strategies ... conference will be held on April 10 through ...
... April 3, 2008 Dendreon Corporation,(Nasdaq: DNDN ) ... with an institutional investor to sell 8.0 million shares ... 8.0 million shares of its,common stock for gross proceeds ... estimated offering expenses, in a,"registered direct" offering. The investor ...
... Offering Broad Array of Healthcare Products to ... with Immune Deficiency and Bleeding Disorders, OTTAWA, ... today,announced that Canadian Blood Services, and Hema-Quebec, have ... (Antihemophilic Factor,[Recombinant]), Humate(R) P (Antihemophilic factor / von ...
Cached Biology Technology:Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies 2Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies 3Dendreon Announces $47 Million Registered Direct Offering 2Dendreon Announces $47 Million Registered Direct Offering 3CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 2CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 3CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 4CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 5CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 6CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 7CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 8
(Date:7/31/2015)... 31, 2015 The 10 th International Conference ... BGI from October 22-25, 2015, in Shenzhen , ... is celebrating its 10 th anniversary this year. Since its ... most influential annual meetings in the ,omics, fields, and is ... ICG-10 focuses on recent breakthroughs and advances ...
(Date:7/23/2015)... 23, 2015 Aware, Inc. (NASDAQ: AWRE ), ... financial results for its second quarter ended June 30, 2015.  ... was $4.5 million, a decrease of 33% compared to $6.8 ... the second quarter of 2015 was $0.3 million, or $0.01 ... per diluted share, in the same period a year ago.  ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... of building a complete, functional, artificial cell. Though this ... many are making progress on various fronts. Prof. Roy ... Material,s and Interfaces Department recently took a significant step ... system on a glass chip. This system, composed of ...
... Researchers Robert Hoare ( Landcare Research , New Zealand) and Erik ... moths after the Minotaur of Greek mythology and the ... of southern pigmy moths . The study was published in ... tiny moths, with wingspans of 3 to 8 millimetres, belong to ...
... the functions of the three enzymes Tan, Ebony and Black ... in neurotransmitter recycling for the visual process. RUB researchers from ... flies cannot see without this recycling. Their analysis of the ... Anna Ziegler, Florian Brsselbach and Bernhard Hovemann report in the ...
Cached Biology News:Cell on a chip reveals protein behavior 2Tiny minotaurs and mini-Casanovas: Ancient pigmy moths reveal secrets of their diversity 2Blind flies without recycling 2Blind flies without recycling 3
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
... activated ,• Eliminates nonspecific products due ... Excellent specificity allows extension through DNA regions ... Leaves an 'A' overhang ,TEMPase ... GeneChoice DNA Polymerase that remains inactive ...
Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
... Probes is pleased to offer the ... ultrasensitive detection of primary amines. Developed ... University, the ATTO-TAG reagents are similar ... naphthalene-2,3-dicarboxaldehyde (NDA) and anthracene-2,3-dicarboxaldehyde, all of ...
Biology Products: